Conclusion: In patients with NHL, it need improve skills immunochemistry to diagnose accurately histo-pathology of DLBCL adapted WHO classification, but at once we will follow-up long term in survival of this patients seperated two subtypes GCB and ABC to evaluate clinically benefit of divide adapted biomarker.